Literature DB >> 18275900

Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation.

Susanne Matthes-Martin1, Ulrike Pötschger, Kirsten Bergmann, Florian Frommlet, Werner Brannath, Peter Bauer, Thomas Klingebiel.   

Abstract

The purpose of the study was to define a risk score for 1-year treatment-related mortality (TRM) in children undergoing allogeneic stem cell transplantation as a basis for risk-adjusted outcome assessment. We analyzed 1364 consecutive stem cell transplants performed in 24 German and Austrian centers between 1998 and 2003. Five well-established risk factors were tested by multivariate logistic regression for predictive power: patient age, disease status, donor other than matched sibling donor, T cell depletion (TCD), and preceding stem cell transplantation. The risk score was defined by rounding the parameter estimates of the significant risk factors to the nearest integer. Crossvalidation was performed on the basis of 5 randomly extracted equal-sized parts from the database. Additionally, the score was validated for different disease entities and for single centers. Multivariate analysis revealed a significant correlation of TRM with 3 risk factors: age >10 years, advanced disease, and alternative donor. The parameter estimates were 0.76 for age, 0.73 for disease status, and 0.97 for donor type. Rounding the estimates resulted in a score with 1 point for each risk factor. One-year TRM (overall survival [OS]) were 5% (89%) with a score of 0, 18% (74%) with 1, 28% (54%) with 2, and 53% (27%) with 3 points. Crossvalidation showed stable results with a good correlation between predicted and observed mortality but moderate discrimination. The score seems to be a simple instrument to estimate the expected mortality for each risk group and for each center. Measuring TRM risk-adjusted and the comparison between expected and observed mortality may be an additional tool for outcome assessment in pediatric stem cell transplantation.

Entities:  

Mesh:

Year:  2008        PMID: 18275900     DOI: 10.1016/j.bbmt.2007.12.487

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  Outcome of invasive mechanical ventilation after pediatric allogeneic hematopoietic SCT: results from a prospective, multicenter registry.

Authors:  J P J van Gestel; M B Bierings; S Dauger; J-H Dalle; P Pavlíček; P Sedláček; L M Monteiro; A Lankester; C W Bollen
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

2.  Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.

Authors:  Emanuele Angelucci; Susanne Matthes-Martin; Donatella Baronciani; Françoise Bernaudin; Sonia Bonanomi; Maria Domenica Cappellini; Jean-Hugues Dalle; Paolo Di Bartolomeo; Cristina Díaz de Heredia; Roswitha Dickerhoff; Claudio Giardini; Eliane Gluckman; Ayad Achmed Hussein; Naynesh Kamani; Milen Minkov; Franco Locatelli; Vanderson Rocha; Petr Sedlacek; Frans Smiers; Isabelle Thuret; Isaac Yaniv; Marina Cavazzana; Christina Peters
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

3.  Earlier Pediatric Psychology Consultation Predicts Lower Stem Cell Transplantation Hospital Costs.

Authors:  Meghan E McGrady; Naomi E Joffe; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2018-05-01

4.  Exhaled nitric oxide and pulmonary complications after paediatric stem cell transplantation.

Authors:  T Fazekas; P Eickhoff; A Lawitschka; B Knotek; U Pötschger; C Peters
Journal:  Eur J Pediatr       Date:  2012-02-16       Impact factor: 3.183

5.  CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity.

Authors:  Barbara Dillinger; Sarah Ahmadi-Erber; Klara Soukup; Angela Halfmann; Silke Schrom; Bernard Vanhove; Peter Steinberger; Rene Geyeregger; Stephan Ladisch; Alexander Michael Dohnal
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.